Idelalisib and Rituximab in 17p Deletion–Positive Splenic Marginal Zone Lymphoma
Journal of the National Comprehensive Cancer Network : JNCCN - United States
doi 10.6004/jnccn.2017.7034
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2018
Authors
Publisher
Harborside Press, LLC